AGTC Genomics Rare Disease Sponsorship Program Strengthens Access to Precision Diagnostics Across Southeast Asia
- Feb 15
- 3 min read
Kuala Lumpur, Malaysia — AGTC Genomics Sdn Bhd (“AGTC Genomics”), a Malaysian deep-tech precision medicine company and ISO 15189 and College of American Pathologists (CAP)–accredited advanced genomics laboratory, continues to accelerate rare disease diagnosis across the region through its expanded Southeast Asia Rare Disease Sponsorship Program, launched in 2025.
Under this regional initiative, AGTC Genomics provides sponsored access to advanced genomic testing for selected rare disease patients across Southeast Asia. In Malaysia, Hospital Kuala Lumpur (HKL) has been one of the key beneficiaries of the program, enabling patients with unresolved and complex conditions to receive comprehensive molecular diagnostics without prolonged delays.
Transforming the Rare Disease Diagnostic Journey
Rare disease patients often endure years of inconclusive testing — a process frequently referred to as the “diagnostic odyssey.” AGTC Genomics addresses this challenge through a structured genomic approach that integrates:
Whole Genome Sequencing (WGS) – Comprehensive detection of single nucleotide variants (SNVs), copy number variants (CNVs), structural variants, and non-coding pathogenic alterations in a single assay.
Whole Exome Sequencing (WES) – High-yield analysis of protein-coding regions responsible for the majority of known monogenic disorders.
Phenotype-Informed NGS Panels – Targeted gene panels curated using detailed clinical presentation and Human Phenotype Ontology (HPO) mapping to maximize diagnostic yield while remaining cost-effective.
By combining deep sequencing with clinical phenotype correlation and advanced bioinformatics interpretation, AGTC shortens time-to-diagnosis and reduces the need for repetitive investigations.
Real Impact Across Borders
Since implementation of the sponsorship initiative, patients in Malaysia and Vietnam have experienced life-changing outcomes.
A Malaysian parent shared:
“We searched for answers for years. After the genomic test, doctors finally understood the root cause. Treatment started early, and today my child is living a normal school life.”
Another Malaysian patient described:
“The clarity from the sequencing result helped not just me, but my family. We finally knew what we were dealing with.”
A patient from Vietnam, referred under the regional program, reflected:
“Instead of trial-and-error treatment, my doctors made a precise decision based on the genomic findings. It saved time, cost, and unnecessary suffering.”
In one case, early molecular identification enabled timely intervention that prevented disease progression and allowed the patient to stabilize and continue leading a productive, independent life — underscoring the clinical and socioeconomic value of precision diagnostics.
Cost-Effective Precision at Scale
While advanced sequencing technologies are often perceived as expensive, AGTC Genomics emphasizes strategic test selection.
For complex or unresolved cases, WGS provides the most comprehensive insight in a single test.
For suspected monogenic conditions, WES offers high diagnostic efficiency.
For clearly defined phenotypes, targeted NGS panels reduce cost while maintaining clinical relevance.
By conducting all tests locally within Malaysia, AGTC Genomics ensures faster turnaround times and improved data sovereignty, while avoiding overseas referral delays.
Strengthening Malaysia’s Rare Disease Ecosystem
AGTC’s sponsorship of the rare disease program at Hospital Kuala Lumpur reflects its broader commitment to strengthening Malaysia’s precision medicine infrastructure and supporting equitable access to advanced diagnostics.
Chee-Onn Leong, PhD, Founder and CEO of AGTC Genomics, said:
“At AGTC Genomics, we believe no rare disease patient should be left without answers simply because advanced testing is inaccessible or delayed. Through our Southeast Asia Rare Disease Sponsorship Program, we are not only funding tests — we are building regional genomic capability, strengthening local expertise, and ensuring that precision diagnostics are delivered where patients live. This is about transforming the standard of care in Southeast Asia and positioning Malaysia as a regional leader in clinical genomics.”
As rare disease awareness grows across Southeast Asia, AGTC Genomics continues to collaborate with hospitals, clinicians, and research partners to expand access to high-quality genomic testing and improve patient outcomes regionally.
About AGTC Genomics Sdn Bhd
AGTC Genomics is a Malaysian precision medicine and advanced molecular diagnostics company specializing in oncology, rare disease genomics, pharmacogenomics, and population genomics. The laboratory operates under ISO 15189 accreditation and provides comprehensive genomic services using state-of-the-art sequencing technologies and clinically validated bioinformatics pipelines.
For media inquiries or collaboration opportunities, please contact:
Comments